BGP Company

Biomanufacturing for Drug Substance (DS)

Leveraging Single-Use Technology for Biosimilars & Vaccines Production, BGP company has implemented a versatile biomanufacturing platform that is dedicated to biological product manufacturing including Biosimilars & Vaccines. 

The platform utilizes state-of-the-art equipment and incorporates single-use technologies (SUT) in both upstream and downstream processes under cGMP. This approach provides flexibility and effectively minimizes the risks associated with contamination.

Let’s discuss your project with Our BGP team

BGP Companny


Scalability is a key aspect of our biomanufacturing capabilities. We utilize a wide range of (SUT) bioreactor capacities to meet diverse project requirements, ranging from 25 L wave bioreactors to robust 2000 L stirred tank bioreactors (STR) for large-scale production. In addition, our upstream lines are further supported by customized perfusion bioreactors, specifically designed to enhance productivity. 

We have the expertise of skilled personnel to manage pre-culture activities, cell culture optimization, and efficient virus handling. Cell Separation: Sophisticated clarification systems, including depth filtration and centrifugation, effectively separate cells from the desired product.

BGP Company


Our purification capabilities are specifically designed to address the requirements of high throughput processing, while also ensuring targeted purification for a diverse range of products. 

By employing advanced dual use Chrome/TFF systems, we have achieved robust purification capabilities with a remarkable processing capacity.

BGP Companny


Drug substances (DS) processing involves various filtration techniques, including nanofiltration and ultrafiltration/Diafiltration (UF/DF).

These filtration methods play a crucial role in separating, purifying, and concentrating the desired biologically active ingredient DS from impurities.

BGP Companny

mRNA platform

BGP demonstrates its dedication to remaining at the forefront of cutting-edge technologies for manufacturing mRNA-based biological products. This commitment is represented by the establishment of a dedicated mRNA vaccine production line that adheres to international cGMP standards.

By leveraging state-of-the-art mRNA technology, BGP is positioned as a significant contributor to advancing vaccine accessibility and innovation, particularly in Africa and other low and middle-income countries (LMICs).